Gabriele Capurso

List of Publications by Year
in descending order

286 papers	10,902 citations	36303 51 h-index	40979 93 g-index
298 all docs	298 docs citations	298 times ranked	12433 citing authors

#	Article	IF	Citations
1	International multidisciplinary survey on the initial management of acute pancreatitis: Perspective of pointâ€ofâ€care specialists focused on daily practice. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 325-337.	2.6	5
2	Exâ€vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DEN Open, 2023, 3, .	0.9	2
3	Analgesia in the Initial Management of Acute Pancreatitis: A Systematic Review and Metaâ€Analysis of Randomised Controlled Trials. World Journal of Surgery, 2022, 46, 878-890.	1.6	12
4	The impact of nutritional status on pancreatic cancer therapy. Expert Review of Anticancer Therapy, 2022, 22, 155-167.	2.4	8
5	Biliary Diseases from the Microbiome Perspective: How Microorganisms Could Change the Approach to Benign and Malignant Diseases. Microorganisms, 2022, 10, 312.	3.6	15
6	Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Endoscopic Ultrasound, 2022, 11, 216.	1.5	5
7	Patient Reported Experience Measure in Endoscopic Ultrasonography: The PREUS Study Protocol. Nursing Reports, 2022, 12, 59-64.	2.1	2
8	Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study. British Journal of Surgery, 2022, 109, 617-622.	0.3	11
9	International external validation of a stratification tool to identify branchâ€duct intraductal papillary mucinous neoplasms at lowest risk of progression. United European Gastroenterology Journal, 2022, 10, 169-178.	3.8	6
10	Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 100, 83-93.	2.2	8
11	The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. Pancreatology, 2022, , .	1.1	1
12	Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study. Pancreatology, 2022, 22, 457-465.	1.1	14
13	â€œCar body appearance and engineâ€: The morphologyâ€function correlation in chronic pancreatitis. United European Gastroenterology Journal, 2022, 10, 361-362.	3.8	1
14	Systematic reviewâ€"pancreatic involvement in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1478-1491.	3.7	18
15	Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature. United European Gastroenterology Journal, 2022, 10, 496-506.	3.8	11
16	Pancreatic resections for benign intraductal papillary mucinous neoplasms: Collateral damages from friendly fire. Surgery, 2022, 172, 1202-1209.	1.9	4
17	A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs. Carcinogenesis, 2022, 43, 728-735.	2.8	5
18	Procalcitonin-guided reduction of antibiotic use in acute pancreatitis. The Lancet Gastroenterology and Hepatology, 2022, , .	8.1	0

#	Article	IF	Citations
19	A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care. Hpb, 2021, 23, 1095-1104.	0.3	12
20	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 273-287.	2.5	32
21	MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. Neuroendocrinology, 2021, 111, 739-751.	2.5	7
22	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Journal of Medical Genetics, 2021, 58, 369-377.	3.2	31
23	The RNAâ€binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Molecular Oncology, 2021, 15, 579-595.	4.6	18
24	Chronic use of statins and acetylsalicylic acid and incidence of postâ€endoscopic retrograde cholangiopancreatography acute pancreatitis: A multicenter, prospective, cohort study. Digestive Endoscopy, 2021, 33, 639-647.	2.3	5
25	Update on gastroenteropancreatic neuroendocrine tumors. Digestive and Liver Disease, 2021, 53, 171-182.	0.9	45
26	COVID-19 and acute pancreatitis: examining the causality. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 3-4.	17.8	107
27	Factors associated with the risk of patients and healthcare workers to develop COVID-19 during digestive endoscopy in a high-incidence area. Gastrointestinal Endoscopy, 2021, 93, 274-275.	1.0	1
28	Incidence and risk factors of oral feeding intolerance in acute pancreatitis: Results from an international, multicenter, prospective cohort study. United European Gastroenterology Journal, 2021, 9, 54-62.	3.8	3
29	ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 2323-2324.	1.5	1
30	Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?. Annals of Surgical Oncology, 2021, 28, 2312-2322.	1.5	5
31	Association of Serum Triglyceride Levels with Severity in Acute Pancreatitis: Results from an International, Multicenter Cohort Study. Digestion, 2021, 102, 809-813.	2.3	7
32	Artificial intelligence in EUS for autoimmune pancreatitis: bias and real life. Gut, 2021, 70, gutjnl-2021-324338.	12.1	0
33	Genomeâ€wide scan of long noncoding <scp>RNA</scp> single nucleotide polymorphism<scp>s</scp> and pancreatic cancer susceptibility. International Journal of Cancer, 2021, 148, 2779-2788.	5.1	23
34	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. European Journal of Internal Medicine, 2021, 84, 63-67.	2.2	18
35	High sensitivity of ROSE-supported ERCP-guided brushing for biliary strictures. Endoscopy International Open, 2021, 09, E363-E370.	1.8	11
36	Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. BMJ Open Gastroenterology, 2021, 8, e000578.	2.7	49

#	Article	IF	Citations
37	Mortality in acute pancreatitis with persistent organ failure is determined by the number, type, and sequence of organ systems affected. United European Gastroenterology Journal, 2021, 9, 139-149.	3.8	13
38	Screening for pancreatic cancerâ€"a compelling challenge. Hepatobiliary Surgery and Nutrition, 2021, 10, 264-266.	1.5	3
39	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Scientific Reports, 2021, 11, 7570.	3.3	2
40	ID: 3522469 RISK OF COVID-19 TRANSMISSION AND OUTCOMES IN HEALTHCARE WORKERS PRESENT DURING GASTROINTESTINAL ENDOSCOPIC PROCEDURES: AN INTERNATIONAL MULTICENTER STUDY. Gastrointestinal Endoscopy, 2021, 93, AB45-AB46.	1.0	0
41	Delay in Pancreatic Endoscopic Ultrasound During the COVID-19 Pandemic in a Pancreas/Tertiary Referral Center. Pancreas, 2021, 50, e54-e55.	1.1	2
42	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis, 2021, 42, 1037-1045.	2.8	14
43	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. Pancreatology, 2021, 21, 1395-1401.	1.1	20
44	A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. Digestive and Liver Disease, 2021, 53, 998-1003.	0.9	12
45	Utility of the â€œ2019 ACR/EULAR classification criteriaâ€•for the management of patients with IgG4-related disease. Seminars in Arthritis and Rheumatism, 2021, 51, 761-765.	3.4	6
46	Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?. Digestive and Liver Disease, 2021, 53, 1065-1067.	0.9	0
47	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Frontiers in Genetics, 2021, 12, 693933.	2.3	10
48	UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterology Journal, 2021, 9, 860-871.	3.8	28
49	Editorial: Hot Topics in Pancreatology From Europe-2020. Frontiers in Medicine, 2021, 8, 724457.	2.6	0
50	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Frontiers in Oncology, 2021, 11, 688889.	2.8	7
51	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2342-2345.	2.5	4
52	Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial. Cancers, 2021, 13, 4512.	3.7	7
53	Infection Control Practices and Outcomes of Endoscopy Units in the Lombardy Region of Italy. Journal of Clinical Gastroenterology, 2021, 55, e87-e91.	2.2	3
54	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. Endoscopic Ultrasound, 2021, 10, 372.	1.5	11

#	Article	IF	Citations
55	Treating Type 2 Autoimmune Pancreatitis With Colchicine: A Case Series. Annals of Internal Medicine, 2021, 174, 1775-1776.	3.9	6
56	Patient-reported experience measure in pancreatobiliary endoscopy: a systematic review to highlight areas for improvement. European Journal of Gastroenterology and Hepatology, 2021, 33, 832-838.	1.6	3
57	Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Frontiers in Oncology, 2021, 11, 771312.	2.8	8
58	The baseline nutritional status assessed by MUST score has a low accuracy in predicting the risk of hospitalization during follow-up in patients with chronic pancreatitis: A cohort study. Pancreatology, 2020, 20, 182-186.	1.1	2
59	Diagnostic performance of endoscopic ultrasound throughâ€theâ€needle microforceps biopsy of pancreatic cystic lesions: Systematic review with metaâ€analysis. Digestive Endoscopy, 2020, 32, 1018-1030.	2.3	49
60	Worldwide Variations in Demographics, Management, and Outcomes of Acute Pancreatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1567-1575.e2.	4.4	64
61	Diagnostic delay does not influence survival of pancreatic cancer patients. United European Gastroenterology Journal, 2020, 8, 81-90.	3.8	20
62	Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Digestive and Liver Disease, 2020, 52, 1126-1130.	0.9	10
63	Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Digestive and Liver Disease, 2020, 52, 1383-1389.	0.9	69
64	RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Cells, 2020, 9, 2561.	4.1	11
65	Endosonography-guided Radiofrequency Ablation in Pancreatic Diseases. Journal of Clinical Gastroenterology, 2020, 54, 591-601.	2.2	7
66	Sa1411 DIAGNOSTIC ACCURACY OF INTRACYSTIC GLUCOSE VS. CEA FOR THE DIAGNOSIS OF MUCINOUS PANCREATIC CYSTIC LESIONS: A META-ANALYSIS. Gastrointestinal Endoscopy, 2020, 91, AB178.	1.0	0
67	Sa1421 GLUCOSE LEVELS IN EUS-ASPIRATED CYST FLUID HAVE A HIGH ACCURACY FOR THE DIAGNOSIS OF MUCINOUS PANCREATIC CYSTIC LESIONS. Gastrointestinal Endoscopy, 2020, 91, AB181.	1.0	3
68	Sa1458 DIAGNOSTIC ACCURACY OF ENDOSCOPIC ULTRASOUND-FINE NEEDLE ASPIRATION (EUS-FNA) IN THE EVALUATION OF PANCREATIC NEUROENDOCRINE NEOPLASMS (PNEN) GRADING. Gastrointestinal Endoscopy, 2020, 91, AB199.	1.0	0
69	Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases â€“ Is It Time to Update the EUâ€™s Orphan Regulation? And if so, What Should be Changed?. Biomedicine Hub, 2020, 5, 1-11.	1.2	11
70	Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. Pancreatology, 2020, 20, 1149-1154.	1.1	3
71	Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer. Frontiers in Medicine, 2020, 7, 495.	2.6	7
72	Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms. JAMA Network Open, 2020, 3, e2022933.	5.9	25

#	Article	IF	Citations
73	How to get away with COVID-19: endoscopy during post-peak pandemic. A perspective review. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482096507.	3.2	5
74	Standardization of a Radiofrequency Ablation Tool in an Ex-Vivo Porcine Liver Model. Gastrointestinal Disorders, 2020, 2, 300-309.	0.8	5
75	Slow-pull compared to suction technique for EUS-guided sampling of pancreatic solid lesions: a meta-analysis of randomized controlled trials. Endoscopy International Open, 2020, 08, E636-E643.	1.8	20
76	955 INHIBITION OF CYCLIN DEPENDENT KINASES OVERCOMES MYCDRIVEN SECONDARY RESISTANCE TO EVEROLIMUS IN DIGESTIVE NETS.. Gastroenterology, 2020, 158, S-195.	1.3	0
77	COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer): Study Protocol. Frontiers in Medicine, 2020, 7, 134.	2.6	6
78	Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency. United European Gastroenterology Journal, 2020, 8, 705-715.	3.8	25
79	Sa1476 IMMUNOMODULATION INDUCED BY ENDOSCOPIC ULTRASOUND-GUIDED ABLATION WITH THE HYBRIDTHERM PROBE IN STAGE III PANCREATIC DUCTAL ADENOCARCINOMA: SINGLE-CENTER PRELIMINARY RESULTS FROM A PHASE II/III RANDOMIZED-CONTROLLED TRIAL. Gastrointestinal Endoscopy, 2020, 91, AB207-AB208.	1.0	0
80	European Guideline on IgG4â€related digestive disease â€“ UEG and SGF evidenceâ€based recommendations. United European Gastroenterology Journal, 2020, 8, 637-666.	3.8	120
81	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology, 2020, 59, 2435-2442.	1.9	46
82	Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2020, 8, 1115-1125.	3.8	49
83	Sa1353 MORTALITY IN PATIENTS WITH ACUTE PANCREATITIS (AP) AND PERSISTENT ORGAN FAILURE (POF) DEPENDS ON NUMBER, TYPE, AND SEQUENCE OF ORGANS AFFECTED. Gastroenterology, 2020, 158, S-327-S-328.	1.3	0
84	The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency. Pancreas, 2020, 49, 793-798.	1.1	3
85	Clinical features of hypertriglyceridemia-induced acute pancreatitis in an international, multicenter, prospective cohort (APPRENTICE consortium). Pancreatology, 2020, 20, 325-330.	1.1	30
86	Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Digestive and Liver Disease, 2020, 52, 392-399.	0.9	28
87	Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: Interim analysis of the prospective PANCY survey. Digestive and Liver Disease, 2020, 52, 547-554.	0.9	21
88	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Cancers, 2020, 12, 275.	3.7	50
89	Genomeâ€wide association study identifies an early onset pancreatic cancer risk locus. International Journal of Cancer, 2020, 147, 2065-2074.	5.1	20
90	Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Endoscopy International Open, 2020, 08, E1511-E1519.	1.8	6

#	Article	IF	Citations
91	Risk for Colorectal Adenomas Among Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms: a Prospective Case- Control Study. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 445-450.	0.9	2
92	Sa1368 ASSOCIATION OF INCREASED SERUM TRIGLYCERIDE LEVELS AND DISEASE SEVERITY IN ACUTE PANCREATITIS: RESULTS FROM AN INTERNATIONAL, MULTICENTER COHORT STUDY. Gastroenterology, 2020, 158, S-335.	1.3	0
93	IgG4-related autoimmune liver disease. Minerva Gastroenterology, 2020, , .	0.5	1
94	Deprescription during last year of life in patients with pancreatic cancer: Optimization or nihilism?. Cancer, 2019, 125, 3470-3471.	4.1	0
95	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2019, 8, 1611.	2.4	11
96	Tu1388 ENDOSCOPIC ULTRASOUND-GUIDED HYBRIDTHERM ABLATION (EUS-HTP) IN PATIENTS (PTS) WITH LOCALLY ADVANCED (LA) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): A CASE-CONTROL COMPARATIVE SURVIVAL ANALYSIS. Gastrointestinal Endoscopy, 2019, 89, AB604-AB605.	1.0	0
97	Tu1345 SLOW-PULL COMPARED TO SUCTION TECHNIQUE FOR EUS-GUIDED SAMPLING OF SOLID PANCREATIC LESIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Gastrointestinal Endoscopy, 2019, 89, AB582-AB583.	1.0	1
98	Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Carcinogenesis, 2019, 40, 544-550.	2.8	8
99	The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs. Digestive and Liver Disease, 2019, 51, 1725-1730.	0.9	7
100	Pancreatic cyst surveillance imposes low psychological burden. Pancreatology, 2019, 19, 1061-1066.	1.1	8
101	Chronic Asymptomatic Pancreatic Hyperenzymemia (CAPH): Meta-analysis of pancreatic findings at second-level imaging. Pancreatology, 2019, 19, 237-244.	1.1	9
102	Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2019, 145, 686-693.	5.1	20
103	Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations. Pancreatology, 2019, 19, 488-499.	1.1	70
104	Surveillance for individuals at highâ€risk of pancreatic cancer: Are we finally heading toward evidence?. United European Gastroenterology Journal, 2019, 7, 341-342.	3.8	2
105	Exocrine pancreatic insufficiency: prevalence, diagnosis, and management . Clinical and Experimental Gastroenterology, 2019, Volume 12, 129-139.	2.3	105
106	Statin use and pancreatic cancer: a risk assessment. Authors? reply. Digestive and Liver Disease, 2019, 51, 750-751.	0.9	1
107	Drug resistance in pancreatic cancer: New player caught in act. EBioMedicine, 2019, 40, 39-40.	6.1	18
108	Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1061-1072.e8.	4.4	32

#	Article	IF	Citations
109	Alcohol and gastrointestinal cancers. Current Opinion in Gastroenterology, 2019, 35, 107-113.	2.3	17
110	Needle-knife fistulotomy vs. standard biliary sphincterotomy for choledocholithiasis: common bile duct stone recurrence and complication rate. Endoscopy International Open, 2019, 07, E1733-E1741.	1.8	10
111	Systematic review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology, 2019, 19, 2-9.	1.1	136
112	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology, 2019, 19, 97-104.	1.1	34
113	Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Digestive and Liver Disease, 2019, 51, 28-37.	0.9	36
114	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. International Journal of Cancer, 2019, 144, 1275-1283.	5.1	36
115	Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. American Journal of Gastroenterology, 2019, 114, 665-670.	0.4	35
116	Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. World Journal of Gastroenterology, 2019, 25, 4343-4359.	3.3	20
117	New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 933-945.	2.0	8
118	Insights into the Rbâ€“Mgâ€“Nâ€“H System: an Ordered Mixed Amide/Imide Phase and a Disordered Amide/Hydride Solid Solution. Inorganic Chemistry, 2018, 57, 3197-3205.	4.0	11
119	Unusual findings in Peutz-Jeghers syndrome: endoscopic and histologic appearance of gastric hamartomatous polyposis with foveolar dysplasia. Gastrointestinal Endoscopy, 2018, 88, 399-400.	1.0	1
120	Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation. British Journal of Surgery, 2018, 105, 328-338.	0.3	41
121	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
122	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Carcinogenesis, 2018, 39, 360-367.	2.8	16
123	Recurrent biliary acute pancreatitis is frequent in a real-world setting. Digestive and Liver Disease, 2018, 50, 277-282.	0.9	16
124	Molecular Pathology of Pancreatic Endocrine Tumors. , 2018, , 209-239.		0
125	European evidence-based guidelines on pancreatic cystic neoplasms. Gut, 2018, 67, 789-804.	12.1	878
126	Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?. European Journal of Cancer, 2018, 95, 123-126.	2.8	11

#	Article	IF	Citations
127	Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. International Journal of Cancer, 2018, 142, 290-296.	5.1	14
128	Clinical Usefulness of 18 Fâ€Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Enteroâ€Pancreatic Neuroendocrine Neoplasms. Oncologist, 2018, 23, 186-192.	3.7	39
129	Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. Oncology Reports, 2018, 39, 1984-1990.	2.6	10
130	Vitamins D and K as Factors Associated with Osteopathy in Chronic Pancreatitis: A Prospective Multicentre Study (P-BONE Study). Clinical and Translational Gastroenterology, 2018, 9, e197.	2.5	44
131	Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study. Digestive and Liver Disease, 2018, 50, 1362-1365.	0.9	7
132	Statin use is not associated with an increased risk of acute pancreatitisâ€"A metaâ€analysis of observational studies. United European Gastroenterology Journal, 2018, 6, 1206-1214.	3.8	11
133	Corrected: Correction: Long-term follow-up of low-risk branchduct IPMNs of the pancreas: is main pancreatic duct dilatation the most worrisome feature?. Clinical and Translational Gastroenterology, 2018, 9, e158.	2.5	22
134	Results of surveillance in individuals at highâ€risk of pancreatic cancer: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 489-499.	3.8	47
135	Pancreatic cystic neoplasms in 2018: The final cut. Endoscopic Ultrasound, 2018, 7, 289.	1.5	3
136	Molecular Pathology of Pancreatic Endocrine Tumors. , 2018, , 1-32.		0
137	Endoscopic ultrasonography of the upper gastrointestinal tract: take a look at the pancreas!. Annals of Gastroenterology, 2018, 31, 637.	0.6	0
138	Prevalence of chronic pancreatitis: Results of a primary care physician-based population study. Digestive and Liver Disease, 2017, 49, 535-539.	0.9	25
139	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Scientific Reports, 2017, 7, 43812.	3.3	15
140	Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management. American Journal of Gastroenterology, 2017, 112, 1153-1161.	0.4	66
141	Early management of acute pancreatitis: A review of the best evidence. Digestive and Liver Disease, 2017, 49, 585-594.	0.9	82
142	Smoking, alcohol and family history of cancer as risk factors for small intestinal neuroendocrine tumors: a systematic review and meta-analysis. Scandinavian Journal of Gastroenterology, 2017, 52, 797-802.	1.5	18
143	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1486-1494.	3.6	27
144	Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms. Endocrine-Related Cancer, 2017, 24, 405-414.	3.1	30

#	Article	IF	Citations
145	Diet and the Risk of Acute Pancreatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 1138-1139.	4.4	0
146	The interaction between smoking, alcohol and the gut microbiome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 579-588.	2.4	144
147	Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Scientific Reports, 2017, 7, 13024.	3.3	39
148	Response to Malleo et al.. American Journal of Gastroenterology, 2017, 112, 1481-1482.	0.4	0
149	The prevalence of pancreatic cystic lesions in patients with liver cirrhosis is double that in controls. United European Gastroenterology Journal, 2017, 5, 1007-1014.	3.8	8
150	Acute Pancreatitis Patient Registry to Examine Novel Therapies in Clinical Experience (Apprentice): An International Multicenter Consortium for the Study of Acute Pancreatitis. Gastroenterology, 2017, 152, S293-S294.	1.3	0
151	Results of Non-Operative Management for Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata or Worrisome Features: A Systematic Review and Meta-Analysis. Gastroenterology, 2017, 152, S681-S682.	1.3	0
152	Surveillance for Pancreatic Cancer in High-Risk Individuals: First-Round Screening Results of a Multicentric Italian Program. Gastroenterology, 2017, 152, S1291.	1.3	1
153	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1349-1351.	2.5	5
154	Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. Cell Death and Disease, 2017, 8, e3168-e3168.	6.3	30
155	The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. International Journal of Molecular Sciences, 2017, 18, 730.	4.1	55
156	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS ONE, 2017, 12, e0179445.	2.5	45
157	Gut microbiota and pancreatic diseases. Minerva Gastroenterology, 2017, 63, 399-410.	0.5	26
158	Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World Journal of Gastrointestinal Endoscopy, 2017, 9, 41.	1.2	44
159	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study.. Journal of Clinical Oncology, 2017, 35, e15774-e15774.	1.6	0
160	Abstract 3411: Rare BRCA2 K3326X increases susceptibility to sporadic pancreatic ductal adenocarcinoma: a PANDoRA study. , 2017, , .		0
161	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
162	A Case of Pancreatic Small Cell Neuroendocrine Carcinoma Associated With SIADH. Pancreas, 2016, 45, e20-e22.	1.1	3

#	Article	IF	Citations
163	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Scientific Reports, 2016, 6, 39565.	3.3	15
164	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. Digestive and Liver Disease, 2016, 48, 473-479.	0.9	78
165	Su1359 Systematic Review and Meta-Analysis: Prevalence of Incidentally Detected Pancreatic Cystic Lesions in Asymptomatic Individuals. Gastroenterology, 2016, 150, S503.	1.3	0
166	Tu1456 Osteopathy Is Common in Patients With Chronic Pancreatitis, but Is Not Related With Vitamin D and Fecal Elastase Levels (P-BONE Study). Gastroenterology, 2016, 150, S906.	1.3	0
167	Tu1459 Prevalence of Chronic Pancreatitis: Results of a Primary Care Physicians Based Population-Study. Gastroenterology, 2016, 150, S907.	1.3	0
168	Colonic small cell neuroendocrine carcinoma in a patient with long-standing ulcerative colitis treated with azathioprine. Digestive and Liver Disease, 2016, 48, 822-823.	0.9	7
169	202 Diabetes, Alcohol Consumption, Family History of Cancer and Obesity as Risk Factors for the Occurrence of Sporadic Pancreatic Neuroendocrine Tumours: A Multicenter European Study (EPINET). Gastroenterology, 2016, 150, S53.	1.3	0
170	Sa1384 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms. Gastroenterology, 2016, 150, S301.	1.3	1
171	Sa1389 Clinical Usefulness of Functional Imaging Tests in the Follow-Up of Digestive Neuroendocrine Neoplasms. Gastroenterology, 2016, 150, S302.	1.3	0
172	1142 Screening for Pancreatic Cancer in High-Risk individuals: Systematic Review and Meta-Analysis. Gastroenterology, 2016, 150, S233.	1.3	0
173	Statin Use and Survival in Resectable Pancreatic Cancer: Confounders and Mechanisms. American Journal of Gastroenterology, 2016, 111, 436.	0.4	1
174	Digestive neuroendocrine neoplasms: A 2016 overview. Digestive and Liver Disease, 2016, 48, 829-835.	0.9	14
175	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis, 2016, 37, 957-964.	2.8	14
176	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. Neuroendocrinology, 2016, 103, 531-537.	2.5	28
177	Deficiency of fat-soluble vitamins in chronic pancreatitis: A systematic review and meta-analysis. Pancreatology, 2016, 16, 988-994.	1.1	69
178	The Use of Complementary and Alternative Medicine is Frequent in Patients With Pancreatic Disorders. Journal of Clinical Gastroenterology, 2016, 50, S161-S163.	2.2	5
179	Systematic review and metaâ€analysis: Small intestinal bacterial overgrowth in chronic pancreatitis. United European Gastroenterology Journal, 2016, 4, 697-705.	3.8	74
180	Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene, 2016, 35, 2031-2039.	5.9	216

#	Article	IF	Citations
181	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	1.8	41
182	Acute pancreatitis patient registry to examine novel therapies in clinical experience (APPRENTICE): an international, multicenter consortium for the study of acute pancreatic. Annals of Gastroenterology, 2016, 30, 106-113.	0.6	28
183	Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. Journal of Clinical Oncology, 2016, 34, 219-219.	1.6	0
184	ERCP-directed radiofrequency ablation of ampullary adenomas: a knife-sparing alternative in patients unfit for surgery. Endoscopy, 2015, 47, E515-E516.	1.8	18
185	Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 594-601.	2.6	20
186	<scp>TERT</scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	5.1	57
187	Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World Journal of Gastrointestinal Endoscopy, 2015, 7, 833.	1.2	28
188	Exocrine Pancreatic Insufficiency in Diabetic Patients: Prevalence, Mechanisms, and Treatment. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	68
189	Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Neuroendocrinology, 2015, 101, 133-142.	2.5	63
190	Early onset pancreatic cancer: Risk factors, presentation and outcome. Pancreatology, 2015, 15, 151-155.	1.1	60
191	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	21.4	224
192	Consensus guidelines on severe acute pancreatitis. Digestive and Liver Disease, 2015, 47, 532-543.	0.9	132
193	Abstract 3455: Functional imaging tests vs. computed tomography scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up. , 2015, , .		0
194	Repeated Transabdominal Ultrasonography Is a Simple and Accurate Strategy to Diagnose a Biliary Etiology of Acute Pancreatitis. Pancreas, 2014, 43, 1106-1110.	1.1	12
195	Small Intestinal Bacterial Overgrowth in Patients With Chronic Pancreatitis. Journal of Clinical Gastroenterology, 2014, 48, S52-S55.	2.2	28
196	Advanced Digestive Neuroendocrine Tumors. Pancreas, 2014, 43, 212-218.	1.1	46
197	Magnetic Resonance Cholangiopancreatography with Secretin Stimulation in the Diagnosis of Intraductal Papillary Mucinous Neoplasm: A Paradigmatic Case Report. Case Reports in Radiology, 2014, 2014, 1-5.	0.3	3
198	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Digestive and Liver Disease, 2014, 46, 479-493.	0.9	108

#	Article	IF	Citations
199	Combined therapy with RAD001 e BEZ235 overcomes resistance of PET cells to mTOR inhibition. Pancreatology, 2014, 14, S111-S112.	1.1	0
200	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
201	Response to Kawakubo et al.. American Journal of Gastroenterology, 2014, 109, 447.	0.4	0
202	Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Digestive and Liver Disease, 2014, 46, 9-17.	0.9	22
203	Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget, 2014, 5, 5381-5391.	1.8	41
204	Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy?. Gland Surgery, 2014, 3, 222-5.	1.1	11
205	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1197-1205.	6.4	50
206	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 2013, 45, 95-99.	0.9	45
207	Outcomes of intraductal papillary mucinous neoplasm with â€œSendai-positiveâ€•criteria for resection undergoing non-operative management. Digestive and Liver Disease, 2013, 45, 584-588.	0.9	22
208	Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene, 2013, 32, 2848-2857.	5.9	115
209	Signalling Pathways Passing Src in Pancreatic Endocrine Tumours: Relevance for Possible Combined Targeted Therapies. Neuroendocrinology, 2013, 97, 67-73.	2.5	10
210	Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. International Journal of Molecular Sciences, 2013, 14, 30-45.	4.1	7
211	Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 320-323.	2.5	20
212	Risk Factors for Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: A Multicentre Caseâ€"Control Study. American Journal of Gastroenterology, 2013, 108, 1003-1009.	0.4	101
213	Celiac Disease and CFTR Mutations in Patients With Chronic Asymptomatic Pancreatic Hyperenzymemia. American Journal of Gastroenterology, 2013, 108, 618.	0.4	4
214	Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Annals of Oncology, 2013, 24, 1907-1911.	1.2	45
215	ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncology Reports, 2013, 29, 1637-1644.	2.6	55
216	Molecular pathology and genetics of pancreatic endocrine tumours. Journal of Molecular Endocrinology, 2012, 49, R37-R50.	2.5	70

#	Article	IF	Citations
217	Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Annals of Oncology, 2012, 23, 1838-1845.	1.2	25
218	Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate. Neuroendocrinology, 2012, 95, 207-213.	2.5	104
219	Meta-analysis. Pancreas, 2012, 41, 1125-1131.	1.1	27
220	Role of the Gut Barrier in Acute Pancreatitis. Journal of Clinical Gastroenterology, 2012, 46, S46-S51.	2.2	121
221	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. Neuroendocrinology, 2012, 96, 32-40.	2.5	55
222	Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. British Journal of Surgery, 2012, 99, 1480-1486.	0.3	128
223	The Role of Src Family Kinases in Neuroendocrine Tumors. Gastroenterology, 2012, 142, e19.	1.3	1
224	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointestinal Endoscopy, 2012, 76, 570-577.	1.0	158
225	Simultaneous intraductal papillary neoplasms of the bile duct and pancreas treated with chemoradiotherapy. World Journal of Gastrointestinal Oncology, 2012, 4, 22.	2.0	18
226	Advanced Digestive Endocrine Tumors: Prognostic Factors Analysis and Patients Stratification According to Metastatic Status. Gastroenterology, 2011, 140, S-873.	1.3	0
227	Contrast Enhanced Ultrasonography (CEUS) and Quantitative Perfusion Analysis in the Assessment of Neuroendocrine Liver Metastases. Gastroenterology, 2011, 140, S-875.	1.3	0
228	Lansoprazole-induced microscopic colitis: An increasing problem? Results of a prospecive case-series and systematic review of the literature. Digestive and Liver Disease, 2011, 43, 380-385.	0.9	37
229	Is Entirely Conservative Management a Correct Strategy for Hemodynamically Stable Patient with a Grade IV Blunt Pancreatic Injury?. World Journal of Surgery, 2011, 35, 933-934.	1.6	6
230	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. Journal of Clinical Oncology, 2011, 29, 2372-2377.	1.6	261
231	Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocrine-Related Cancer, 2011, 18, 541-554.	3.1	32
232	Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. Neuroendocrinology, 2011, 93, 223-229.	2.5	103
233	Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway. Journal of Clinical Oncology, 2010, 28, 245-255.	1.6	497
234	Epidemiology, Risk Factors and Clinical Presentation. Medical Radiology, 2010, , 3-10.	0.1	0

#	Article	IF	Citations
235	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Digestive and Liver Disease, 2010, 42, 457-458.	0.9	7
236	Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours. Digestive and Liver Disease, 2010, 42, 173-174.	0.9	3
237	Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry. Digestive and Liver Disease, 2010, 42, 597-605.	0.9	38
238	Italian consensus guidelines for chronic pancreatitis. Digestive and Liver Disease, 2010, 42, S381-S406.	0.9	140
239	Nasogastric or nasointestinal feeding in severe acute pancreatitis. World Journal of Gastroenterology, 2010, 16, 3692.	3.3	28
240	Molecular Pathology of Pancreatic Endocrine Tumors. , 2010, , 171-197.		0
241	Risk Factors for Sporadic Pancreatic Endocrine Tumors. American Journal of Gastroenterology, 2009, 104, 3034-3041.	0.4	52
242	Methodology and Indications of H₂â€Breath Testing in Gastrointestinal Diseases: the Rome Consensus Conference. Alimentary Pharmacology and Therapeutics, 2009, 29, 1-49.	3.7	320
243	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. Critical Reviews in Oncology/Hematology, 2009, 72, 110-124.	4.4	36
244	Endoscopic Management of Type I Gastric Carcinoid and Recurrence Rate. Gastrointestinal Endoscopy, 2009, 69, AB112.	1.0	0
245	Phenotype Expression in a Case of Adult Cystic Fibrosis Caused by an Extremely Rare Compound Heterozygous Genotype (2183AA>G/2789+5G>A). Pancreas, 2009, 38, 599-601.	1.1	1
246	Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer. Cancer, 2008, 112, 671-672.	4.1	2
247	Probiotics and Severe Acute Pancreatitis. Journal of Clinical Gastroenterology, 2008, 42, S148-S151.	2.2	9
248	ADDENDUM. Journal of Clinical Gastroenterology, 2008, 42, S152-S153.	2.2	3
249	Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocrine-Related Cancer, 2007, 14, 111-124.	3.1	52
250	A Critical View of Molecularly Target Therapy for Digestive Endocrine Tumours. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 119-126.	0.6	0
251	Rhabdomyolysis due to severe hypokaliemia in a Crohn's disease patient after budesonide treatment. Digestive and Liver Disease, 2007, 39, 776-779.	0.9	10
252	Metaâ€analysis: the use of nonâ€steroidal antiâ€inflammatory drugs and pancreatic cancer risk for different exposure categories. Alimentary Pharmacology and Therapeutics, 2007, 26, 1089-1099.	3.7	38

#	Article	IF	Citations
253	Probiotics and the incidence of colorectal cancer: when evidence is not evident. Digestive and Liver Disease, 2006, 38, S277-S282.	0.9	46
254	Corpus-predominant gastritis as a risk factor for false-negative13C-urea breath test results. Alimentary Pharmacology and Therapeutics, 2006, 24, 1453-1460.	3.7	26
255	Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Annals of Oncology, 2006, 17, 461-466.	1.2	120
256	Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocrine-Related Cancer, 2006, 13, 541-558.	3.1	98
257	Endocrine tumours of the stomach. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 659-673.	2.4	72
258	Peanut-Like 1 (Septin 5) Gene Expression in Normal and Neoplastic Human Endocrine Pancreas. Neuroendocrinology, 2005, 81, 311-321.	2.5	19
259	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer, 2005, 12, 1083-1092.	3.1	360
260	Of Bacteria, Acid, and Blood. Gastroenterology, 2005, 129, 1139-1140.	1.3	0
261	Proteomic Analysis of Chronic Pancreatitis and Pancreatic Adenocarcinoma. Gastroenterology, 2005, 129, 1454-1463.	1.3	162
262	Gastric Neuroendocrine Tumors. Neuroendocrinology, 2004, 80, 16-19.	2.5	41
263	Re: Etiology of Pancreatic Cancer, With a Hypothesis Concerning the Role of N-Nitroso Compounds and Excess Gastric Acidity. Journal of the National Cancer Institute, 2004, 96, 75-75.	6.3	6
264	Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. Alimentary Pharmacology and Therapeutics, 2004, 19, 663-670.	3.7	46
265	Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. International Journal of Colorectal Disease, 2004, 19, 545-553.	2.2	45
266	Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis. Gastrointestinal Endoscopy, 2004, 59, 766-771.	1.0	52
267	Intragastric Ascorbic But Not Uric Acid is Depleted in Relation with the Increased pH in Patients with Atrophic Body Gastritis and H. Pylori Gastritis. Helicobacter, 2003, 8, 300-306.	3.5	25
268	DXA vs. QCT for subclinical celiac disease patients. Acta Diabetologica, 2003, 40, s174-s176.	2.5	4
269	Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy. Digestive and Liver Disease, 2003, 35, 869-875.	0.9	28
270	The stomach and iron deficiency anaemia: a forgotten link. Digestive and Liver Disease, 2003, 35, 288-295.	0.9	80

#	Article	IF	Citations
271	Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Digestive and Liver Disease, 2003, 35, 784-787.	0.9	22
272	Large hiatal hernia is a underdiagnosed disease in patients with iron deficiency anemia. Gastroenterology, 2003, 124, A627.	1.3	2
273	Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia. Gut, 2003, 52, 496-501.	12.1	152
274	Endoscopic Evaluation of the Upper Gastrointestinal Tract is Worthwhile in Premenopausal Women with Iron-Deficiency Anaemia Irrespective of Menstrual Flow. Scandinavian Journal of Gastroenterology, 2003, 38, 239-245.	1.5	37
275	Timing and sampling in surveillance of premalignant gastric lesions. Gut, 2002, 51, 896-897.	12.1	2
276	Consequences of Helicobacter pylori infection on the absorption of micronutrients. Digestive and Liver Disease, 2002, 34, S72-S77.	0.9	56
277	Iron Deficiency Anaemia Caused by Nonspecific (Idiopathic) Small Bowel Ulceration: An Uncommon Presentation of an Uncommon Disease. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 855-859.	1.7	9
278	The longâ€term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Alimentary Pharmacology and Therapeutics, 2002, 16, 1723-1731.	3.7	75
279	Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. American Journal of Medicine, 2001, 111, 439-445.	1.5	180
280	Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2001, 15, 821-829.	3.7	18
281	Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated withHelicobacter pyloriinfection. Alimentary Pharmacology and Therapeutics, 2001, 15, 1753-1761.	3.7	73
282	Magnetic resonance imaging (MRI) in the management of patients with Crohn's disease (CD): An index of effectiveness in course of therapy with anti-TNF antibodies. Gastroenterology, 2000, 118, A321.	1.3	0
283	Gi diseases causing iron malabsorption are more frequent than GI bleeding lesions in iron deficiency anemia (IDA) patients: A prospective study. Gastroenterology, 2000, 118, A458.	1.3	0
284	Iron deficiency anaemia and Helicobacter pylori infection. International Journal of Antimicrobial Agents, 2000, 16, 515-519.	2.5	54
285	Iron-Deficiency Anemia in Premenopausal Women: Why Not Consider Atrophic Body Gastritis and Helicobacter pylori Role?. American Journal of Gastroenterology, 1999, 94, 3084-3085.	0.4	23
286	Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). International Journal of Epidemiology, 1998, 27, 397-404.	1.9	151